Santen Pharmaceutical Co Ltd at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 06:30PM GMT
Naomi Kumagai - JP Morgan Chase & Co, Research Division - Senior Analyst

Good morning, everyone. Welcome to the conference. My name is Naomi Kumagai, Japan pharma analyst at the JPMorgan. It's my great pleasure to introduce Mr. Taniuchi, President and COO of Santen. There's no breakout after the presentation but management is available for one-on-one. With that, over to Taniuchi.

Shigeo Taniuchi - Santen Pharmaceutical Co., Ltd. - President, COO, Head of North America Business & Director

Good morning, everyone. Thank you for joining us. I am Shigeo Taniuchi, President and COO of Santen.

I'm glad to be here. I'll come back again to make a presentation at JPMorgan Healthcare Conference 2020.

Today, in next 20, 25 minutes, I'd like to explain about the Santen and its projects. How we are going to contribute to patients suffering from eye conditions, eye diseases by focusing on innovation in ophthalmology field and explain how we continue our growth.

So first of all, I'd like to start from who we are. Because as a specialty

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot